Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENSBiotechnology
-$0.02 today
- Market cap
- $141.41M
- Beta
- 2.08
- P/E (TTM)
- -25.1
- EPS (TTM)
- -$0.06
Volume 0.07M
Average 0.10M
MENS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS
Depreciation & Amortization · Q4 FY2024 · quarter ended Dec 2024
Depreciation & amortization declines year over year
Q4 FY2024 depreciation & amortization of $29 fell 6.5% year over year. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 100K USD
- Year-over-year change
- -16.7%
- 4-year CAGR
- -4.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 100K | -16.7% |
| FY2024 | 2024-12-31 | 120K | -5.5% |
| FY2023 | 2023-12-31 | 127K | +3.3% |
| FY2022 | 2022-12-31 | 123K | +0.8% |
| FY2021 | 2021-12-31 | 122K | — |
Depreciation & Amortization vs competitors
How MENS compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Over three fiscal years its annual growth of -6.7% compares with a peer median of +21.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥86.48M CNY | -7.2% | +11.2% | 15.5% |
| LTM Sep 2026 | $52.78M USD | -3.5% | +43.1% | 8.1% | |
| LTM Sep 2026 | $50.27M USD | +111.9% | +16.3% | 3.7% | |
| LTM Mar 2026 | $13.62M USD | -61.8% | +24.3% | 2.0% | |
| LTM Sep 2026 | $3.7M USD | +520.0% | +358.4% | 59.9% | |
| LTM Sep 2026 | $2.32M USD | -9.6% | +21.9% | — | |
| LTM Jun 2026 | $2.15M USD | +13.8% | +6.8% | — | |
| LTM Jun 2026 | $1.63M USD | +123.2% | — | — | |
| LTM Mar 2026 | $943K USD | +2.9% | +91.6% | — | |
| LTM Jun 2026 | $196K USD | +34.0% | -7.5% | — | |
| LTM Dec 2024 | $120 USD | — | -6.7% | — | |
| Peer median (excluding MENS) | — | +8.3% | +21.9% | 8.1% | |
Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.2M) | (6.63M) | (4.4M) | (3.02M) | (4.67M) |
| Depreciation & Amortization | 122K | 123K | 127K | 120K | 100K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.24M | 2.94M | 1.12M | (1.49M) | 20.74M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 21K | (28K) | (2K) | 1K | (1K) |
| Other Working Capital | 1.22M | 2.97M | 1.12M | (1.49M) | 20.74M |
| Other Non-Cash Items | 849K | 599K | 554K | 761K | (19.21M) |
| Operating Cash Flow | (1.98M) | (2.97M) | (2.6M) | (3.62M) | (3.04M) |
| Capital Expenditures | (137K) | (246K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (1.83M) | (292K) | 0 | 0 | (16.87M) |
| Sales of Investments | 664K | 1.93M | 95K | 0 | 16.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (13.51M) |
| Investing Cash Flow | (1.31M) | 1.39M | 95K | 0 | (13.51M) |
| Debt Repayment | (1.35M) | 3.61M | 2.47M | 2.2M | (24K) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 17.77M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (35K) | (276K) | (445K) | (213K) | (114K) |
| Financing Cash Flow | (1.38M) | 3.33M | 2.03M | 1.99M | 17.63M |
| Effect of Forex Changes | 67K | (31K) | (54K) | (7K) | (8K) |
| Net Change in Cash | (4.61M) | 1.72M | (532K) | (1.64M) | 1.08M |
| Free Cash Flow | (2.12M) | (3.22M) | (2.6M) | (3.62M) | (3.04M) |
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
Intrinsic Alpha fair value
Locked
Current Price
$1.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.